Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

On firm ground: IP protection of therapeutic nanoparticles

Nature Biotechnology volume 28, pages 1267–1270 (2010)Cite this article

Subjects

The development of generic therapeutic nanoparticles faces a combination of scientific, patent and regulatory challenges.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Market exclusivity: therapeutic nanoparticle versus conventional drug product.
Figure 2

References

  1. Doxil Product Information. Ortho Biotech Products, LP (2008).

  2. Farokhzad, O. & Langer, R. ACS Perspective 3, 16–20 (2009).

    CAS  Google Scholar 

  3. Davis, M. Nanotechnol. Law & Bus. 255–262 (September 2006).

  4. US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm

  5. US Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf (March 2003).

  6. US Food and Drug Administration. Advisory Committee For Pharmaceutical Science Proceedings http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3763t2.htm (July 20, 2001).

  7. US Food and Drug Administration. Critical Path Opportunities for Generic Drugs http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077250.htm (May 1, 2007).

  8. US Food and Drug Administration. Draft guidance on doxorubicin hydrochloride http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM199635.pdf (February 2010).

  9. 21 CFR 314.94(a)(iii).

Download references

Author information

Authors and Affiliations

  1. Paul Burgess, Scott Minick and Stephen Zale are at BIND Biosciences, Cambridge, Massachusetts, USA.,

    Paul Burgess, Scott Minick & Stephen Zale

  2. Peter Barton Hutt is at Covington & Burling, Washington, DC, USA.,

    Peter Barton Hutt

  3. Omid C. Farokhzad is at Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.,

    Omid C Farokhzad

  4. Robert Langer is at Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.,

    Robert Langer

Authors
  1. Paul Burgess
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Barton Hutt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omid C Farokhzad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Langer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Scott Minick
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Stephen Zale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Burgess.

Ethics declarations

Competing interests

P.B.H., O.C.F. and R.L. have a financial interest in BIND Biosciences.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burgess, P., Hutt, P., Farokhzad, O. et al. On firm ground: IP protection of therapeutic nanoparticles. Nat Biotechnol 28, 1267–1270 (2010). https://doi.org/10.1038/nbt.1725

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1725

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing